The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Snigdha Vankineni
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Snigdha Vankineni, a member of the promoter group of Oxygenta Pharmaceutical Ltd, sold 6,00,000 equity shares (1.62% of equity capital) on April 16, 2025, pursuant to a Share Purchase Agreement dated September 30, 2024. This was an off-market transaction. As a result, her holding in the company reduced from 11,43,000 shares (3.09%) to 5,43,000 shares (1.47%). The total equity share capital of the company remains 3,69,83,500 shares of Rs. 10 each, amounting to Rs. 36,98,35,000. The disclosure was filed under SEBI SAST Regulation 29(2) on April 19, 2025.
This is a promoter-group stake sale of over 1% through a private agreement, which can be viewed as a mild negative signal for retail investors as it reflects a promoter reducing exposure. However, the absolute promoter holding was already small (3.09%), so the impact on overall promoter control is limited. The off-market nature suggests a pre-arranged buyer rather than a broader market sentiment indicator.